Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387088 · ClinicalTrials.gov registry record · Phase 3
Tiotropium / Respimat One Year Study in COPD.
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,991
- Enrollment target
NCT00387088: Completed Phase 3 study, sponsored by Boehringer Ingelheim.
NCT00387088 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 3,991 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (417% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00387088, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,991 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.
Primary Outcome
Trough FEV1 is defined as the FEV1 measured at the -10 min time point at the end of the dosing interval (24 h post drug administration).
Interventions
- DRUG Tiotropium
- DEVICE Respimat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,991 participants |
| Start Date | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00387088 record still lists
NCT00387088 is an interventional study that assigns participants to a tested intervention. Its 3,991 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (417% higher).
The record links to 0 conditions, and to 2 interventions - of which Tiotropium is the first listed.
NCT00387088 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00387088 about?
NCT00387088 is a clinical study titled "Tiotropium / Respimat One Year Study in COPD.". The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.
What is the current status of trial NCT00387088?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,991 participants. The study started on 2006-09.
What interventions are being tested in trial NCT00387088?
The interventions under investigation include: Tiotropium (DRUG), Respimat (DEVICE).
Who is sponsoring clinical trial NCT00387088?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00387088's enrollment target sits among peer trials
3,991 63rd of 2000 higher than 1,938 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia